Calidi Biotherapeutics Appoints Experienced Life Science Leader Eric Poma as New CEO
Calidi Biotherapeutics has named Dr. Eric Poma as its new Chief Executive Officer, bringing over 30 years of life science expertise to guide the company's innovative cancer therapy development strategy.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has appointed Dr. Eric Poma as its new Chief Executive Officer and board member, signaling a strategic leadership transition for the biotechnology company. Poma brings more than three decades of experience in life sciences to the role, succeeding Allan Camaisa, who will continue to serve on the board.
Dr. Poma's extensive background is expected to be instrumental in advancing the company's proprietary cancer therapies. Research suggests that companies with experienced leadership are 2.3 times more likely to outperform competitors financially, highlighting the potential significance of this executive appointment.
The leadership change demonstrates Calidi Biotherapeutics' commitment to driving innovation and strategic growth in the competitive biotechnology sector. With Poma's proven expertise, the company aims to accelerate its therapy development efforts and strengthen its market position.